| $337M | ||
| $259M | ||
| $79M | ||
| $60M | ||
| $58M | ||
| $50M |
Buys | $0 | 0 | 0 |
Sells | $559,900 | 11 | 100 |
| Gaskins Tammi L | Chief Commercial Officer | 0 | $0 | 1 | $1,487 | $-1,487 |
| Martini Gregory S. | Chief Financial Officer | 0 | $0 | 1 | $21,212 | $-21,212 |
| Davis Andrew | SVP, Chief Business Officer | 0 | $0 | 1 | $21,869 | $-21,869 |
| Silver Ronald | Principal Accounting Officer | 0 | $0 | 2 | $34,471 | $-34,471 |
| Emany Sravan Kumar | SVP, COO and CFO | 0 | $0 | 1 | $44,884 | $-44,884 |
| Shetzline Michael | SVP, CMO, Head-Res&Drug | 0 | $0 | 1 | $72,633 | $-72,633 |
| John Minardo | Chief Legal Officer | 0 | $0 | 2 | $110,847 | $-110,847 |
| MCCOURT Thomas A | Chief Executive Officer | 0 | $0 | 2 | $252,497 | $-252,497 |
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
Over the last 12 months, insiders at Ironwood Pharmaceuticals, Inc. have bought $0 and sold $559,900 worth of Ironwood Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Ironwood Pharmaceuticals, Inc. have bought $11.71M and sold $4.25M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 6,920 shares for transaction amount of $60,204 was made by Duane Jon R (director) on 2024‑03‑06.
| 2025-05-16 | Sale | MCCOURT Thomas A | Chief Executive Officer | 13,353 0.0084% | $0.58 | $7,745 | +8.59% | |
| 2025-05-16 | Sale | Gaskins Tammi L | Chief Commercial Officer | 2,563 0.0016% | $0.58 | $1,487 | +8.59% | |
| 2025-02-10 | Sale | MCCOURT Thomas A | Chief Executive Officer | 139,064 0.0889% | $1.76 | $244,753 | -45.88% | |
| 2025-02-10 | Sale | Shetzline Michael | SVP, CMO, Head-Res&Drug | 41,269 0.0264% | $1.76 | $72,633 | -45.88% | |
| 2025-02-10 | Sale | John Minardo | Chief Legal Officer | 38,938 0.0249% | $1.76 | $68,531 | -45.88% | |
| 2025-02-10 | Sale | Silver Ronald | Principal Accounting Officer | 12,048 0.0077% | $1.76 | $21,204 | -45.88% | |
| 2025-02-10 | Sale | Martini Gregory S. | Chief Financial Officer | 12,052 0.0077% | $1.76 | $21,212 | -45.88% | |
| 2024-11-18 | Sale | Emany Sravan Kumar | SVP, COO and CFO | 11,001 0.007% | $4.08 | $44,884 | -61.69% | |
| 2024-11-18 | Sale | Davis Andrew | SVP, Chief Business Officer | 5,360 0.0034% | $4.08 | $21,869 | -61.69% | |
| 2024-08-12 | Sale | John Minardo | Chief Legal Officer | 9,910 0.0063% | $4.27 | $42,316 | -16.75% | |
| 2024-08-12 | Sale | Silver Ronald | Principal Accounting Officer | 3,107 0.002% | $4.27 | $13,267 | -16.75% | |
| 2024-06-10 | Sale | McHugh Julie | director | 22,766 0.0138% | $6.29 | $143,198 | -39.76% | |
| 2024-06-07 | Sale | Moukheibir Catherine | director | 35,574 0.0233% | $6.61 | $235,144 | -37.64% | |
| 2024-06-06 | Sale | Moukheibir Catherine | director | 44,426 0.0276% | $6.36 | $282,549 | -38.60% | |
| 2024-05-20 | Sale | MCCOURT Thomas A | Chief Executive Officer | 67,618 0.0427% | $6.45 | $436,136 | -36.60% | |
| 2024-05-20 | Sale | Shetzline Michael | CMO,SVP,Head-Res&Drug | 16,128 0.0102% | $6.45 | $104,026 | -36.60% | |
| 2024-05-20 | Sale | John Minardo | Chief Legal Officer | 17,404 0.011% | $6.45 | $112,256 | -36.60% | |
| 2024-05-20 | Sale | Davis Andrew | SVP, Chief Business Officer | 22,725 0.0144% | $6.45 | $146,576 | -36.60% | |
| 2024-03-06 | Duane Jon R | director | 6,920 0.0045% | $8.70 | $60,204 | -46.75% | ||
| 2024-03-04 | Emany Sravan Kumar | SVP, Chief Financial Officer | 10,684 0.0069% | $9.38 | $100,216 | -50.32% |
| MCCOURT Thomas A | Chief Executive Officer | 1147281 0.709% | $711,314.22 | 0 | 35 | |
| Shetzline Michael | SVP, CMO, Head-Res&Drug | 554007 0.3424% | $343,484.34 | 0 | 11 | |
| John Minardo | Chief Legal Officer | 408132 0.2522% | $253,041.84 | 0 | 8 | |
| Emany Sravan Kumar | SVP, COO and CFO | 309572 0.1913% | $191,934.64 | 2 | 2 | <0.0001% |
| Davis Andrew | SVP, Chief Business Officer | 284685 0.1759% | $176,504.70 | 0 | 8 | |
| Silver Ronald | Principal Accounting Officer | 279655 0.1728% | $173,386.10 | 0 | 13 | |
| Gaskins Tammi L | Chief Commercial Officer | 242596 0.1499% | $150,409.52 | 0 | 1 | |
| Martini Gregory S. | Chief Financial Officer | 183810 0.1136% | $113,962.20 | 0 | 1 | |
| DENNER ALEXANDER J | 16390000 10.1285% | $10.16M | 8 | 0 | +18.72% | |
| Ridgeback Capital Investments L.P. | 10 percent owner | 6842839 4.2287% | $4.24M | 3 | 42 | <0.0001% |
| Hecht Peter M | Chief Executive Officer | 4696917 2.9026% | $2.91M | 1 | 16 | +9.03% |
| FMR LLC | 10 percent owner | 837736 0.5177% | $519,396.32 | 0 | 43 | |
| Currie Mark G | 521758 0.3224% | $323,489.96 | 0 | 37 | ||
| Mallon Mark | Chief Executive Officer | 470605 0.2908% | $291,775.10 | 0 | 4 | |
| Consylman Gina | SVP, CFO & Treasurer | 336244 0.2078% | $208,471.28 | 0 | 17 | |
| Rickard Jason | SVP, Chief Operating Officer | 332648 0.2056% | $206,241.76 | 0 | 15 | |
| Higgins Michael J | Chief Operating Officer | 300000 0.1854% | $186,000.00 | 0 | 7 | |
| Gilbert Halley E | Chief Admin Officer & SVP | 265991 0.1644% | $164,914.42 | 0 | 14 | |
| Owens Edward P | director | 218954 0.1353% | $135,751.48 | 4 | 0 | +34.25% |
| McHugh Julie | director | 139528 0.0862% | $86,507.36 | 0 | 12 | |
| Kilroy Conor | SVP, GC & Secretary | 122336 0.0756% | $75,848.32 | 0 | 3 | |
| Duane Jon R | director | 121028 0.0748% | $75,037.36 | 1 | 0 | <0.0001% |
| Kessler Marla L | director | 96572 0.0597% | $59,874.64 | 0 | 2 | |
| MacDonald Kelly | Chief Accounting Officer | 93041 0.0575% | $57,685.42 | 0 | 9 | |
| OLANOFF LAWRENCE S | director | 68629 0.0424% | $42,549.98 | 0 | 17 | |
| Moukheibir Catherine | director | 48633 0.0301% | $30,152.46 | 0 | 2 | |
| COOK JOSEPH C JR | director | 42775 0.0264% | $26,520.50 | 0 | 6 | |
| Graney Thomas | Chief Financial Officer | 20763 0.0128% | $12,873.06 | 0 | 2 | |
| Fanucci Marsha | director | 19778 0.0122% | $12,262.36 | 1 | 1 | <0.0001% |
| MCGUIRE TERRANCE | director | 0 0% | $0 | 0 | 1 | |
| ROBERTS BRYAN E | director | 0 0% | $0 | 0 | 13 |
$2,051,022 | 1591 | -12.84% | $78.4M | |
$22,899,264 | 81 | 34.90% | $19.09M | |
$218,350,131 | 64 | 16.68% | $231.89M | |
$125,860,243 | 57 | -4.48% | $32.12M | |
$129,489,279 | 57 | 26.09% | $389.44M | |
$2,740,482 | 50 | 9.37% | $31.51M | |
$33,884,330 | 45 | 12.58% | $454.37M | |
$30,209,812 | 45 | -1.91% | $13.54M | |
$6,021,989 | 30 | -0.17% | $339.7M | |
$3,140,759 | 30 | 10.79% | $13.76M | |
$423,174,478 | 29 | -7.58% | $27.75M | |
$17,389,773 | 25 | -6.03% | $292.86M | |
Ironwood Pharmaceuticals, Inc. (IRWD) | $25,034,841 | 20 | 9.38% | $100.33M |
$758,061 | 9 | 60.03% | $157.72M | |
$1,683,154 | 8 | 46.59% | $414.31M | |
$179,515 | 7 | 1.51% | $339.24M | |
$103,523 | 3 | 9.40% | $60.52M | |
$999,999 | 1 | -52.42% | $16.76M | |
$5,003,136 | 1 | -14.58% | $249.18M |
| Increased Positions | 106 | +40.3% | 37M | +22.37% |
| Decreased Positions | 114 | -43.35% | 46M | -27.92% |
| New Positions | 31 | New | 3M | New |
| Sold Out Positions | 51 | Sold Out | 4M | Sold Out |
| Total Postitions | 255 | -3.04% | 156M | -5.54% |
| Vanguard Group Inc | $18,210.00 | 12.06% | 19.54M | -2M | -11.34% | 2024-12-31 |
| Sarissa Capital Management Lp | $15,275.00 | 10.12% | 16.39M | 0 | 0% | 2024-12-31 |
| Blackrock, Inc. | $11,071.00 | 7.33% | 11.88M | -11M | -48.44% | 2025-03-31 |
| Pacer Advisors, Inc. | $10,933.00 | 7.24% | 11.73M | +450,949 | +4% | 2024-12-31 |
| Armistice Capital, Llc | $8,824.00 | 5.84% | 9.47M | +1M | +15.46% | 2024-12-31 |
| Renaissance Technologies Llc | $8,450.00 | 5.6% | 9.07M | +469,043 | +5.46% | 2024-12-31 |
| State Street Corp | $7,762.00 | 5.14% | 8.33M | -2M | -16.04% | 2024-12-31 |
| Braidwell Lp | $5,070.00 | 3.36% | 5.44M | +1M | +22.58% | 2024-12-31 |
| Kynam Capital Management, Lp | $4,367.00 | 2.89% | 4.69M | +1M | +27.13% | 2024-12-31 |
| Lsv Asset Management | $3,804.00 | 2.52% | 4.08M | -970,100 | -19.2% | 2024-12-31 |